Training Example: Novartis – Review the Data, Give Your Score & Compare to the Real AI Evaluation

For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medicines that redefine the future for patients.

[IMG: Q1 2026 results]

[H2]
Novartis Financial Results - Q1 2026

Novartis announces the company’s financial results for the first quarter of 2026.

Learn more

Previous

Next

[IMG: Happy father with daughter on his shoulders under a clear blue sky]

Therapeutic areas

[H2]
Discover our medicines

[IMG: Close up on the hands of a laboratory technician wearing blue gloves preparing a sample with pipette]

Research and development

[H2]
Explore our science

[IMG: HCP wearing a medical coat pulling a cart bicycle in rural african village]

ESG

[H2]
Learn about our impact

[IMG: Two business people smiling in a modern and bright room]

Careers

[H2]
Join our team

[H2]
Latest news

May 07, 2026
Press release

[H3] Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Apr 30, 2026
Press release

[H3] Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Apr 28, 2026
Ad hoc release

[H3] Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

All news

[IMG: Scientist in protective gear working in a laboratory]

[H2]
Manufacturing expansion in the United States

Novartis is expanding our manufacturing and R&D facilities in the US to scale innovation, help patients and create jobs.

Learn more

[IMG: Child having medical examination]

[H2]
Bringing breakthroughs to more patients

At Novartis, we don’t just discover life-changing medicines, we're part of a broader effort to help ensure medicines reach the people who need them most, wherever they live, because the true value of innovation lies in its ability to improve lives.

Read our full statement

[IMG: Portrait of Michael Williams playing electric guitar]

Patient story

[H2]
Live. Magazine

Live is the in-house magazine of Novartis which is now available in a digital format. Explore stories, podcasts and more from across the company.

Discover Michael's story

[IMG: Business people walking on the Novartis Basel campus]

[H2]
Annual reporting suite

Explore and download our Annual Report 2025, Report on Nonfinancial Matters 2025 and other reporting documents.

Learn more

[H2]
Resource links

About Novartis
Patients and caregivers
Healthcare professionals
Clinical trials
Pipeline
Products

At Novartis, we use science-based innovation to address some of society’s most challenging healthcare issues. We discover and develop breakthrough treatments and find new ways to deliver them to as many people as possible. As a global company, we have a great responsibility and an even greater opportunity to lead the world in creating a positive social change, embracing societal impact as a core business objective.

[IMG: Business people walking on the Novartis Basel campus]

[H2]
Report on Nonfinancial Matters 2025

This report covers information on nonfinancial matters deemed material and in scope of our reporting obligations under the Swiss Code of Obligations (SCO), as well as our due diligence and reporting obligations in relation to child labor under the SCO.​It includes our Human Rights Statement addressing specific jurisdictional requirements for disclosure on modern slavery, decent work, forced labor and child labor.​Download the report (PDF 1.0 MB) | HTML (ZIP 0.9 MB)

[IMG: A female health worker talking a male patient through his medication steps and holding a bottle of pills in her hand.]

[H2]
Annual Social Impact and Sustainability investor event

Our 12th annual Social Impact & Sustainability investor event provided updates on the impact we continue to deliver through inclusive access to innovation and environmental sustainability.View the event presentation (PDF 2.1 MB)For more recent progress, we provide a quarterly impact and sustainability update. Q1 2026 Impact and Sustainability Update (PDF 1.6 MB)Q4 2025 Impact and Sustainability Update (PDF 1.0 MB)Q3 2025 Impact and Sustainability Update (PDF 0.8 MB)Q2 2025 Impact and Sustainability Update (PDF 0.8 MB)

[H2] ESG strategic priorities
Building trust with society is a key part of the Novartis corporate strategy and is critical to delivering on our purpose of reimagining medicine to improve and extend people’s lives. Our ESG efforts are integrated across the company and are key to driving long-term sustainable value for our stakeholders.We believe our inspired, curious and unbossed culture will drive better performance. ESG topics form a core component of how the Novartis Executive Committee and the Board of Directors evaluate long-term performance of the company. We are committed to reporting transparently on these topics through our Reporting and Transparency Hub, which includes the Report on Nonfinancial Matters (PDF 1.0 MB), as well as our other publications.

[IMG: Doctor in Rwanda weighing a baby]

[H2]
Access

We are committed to expanding access to our medicines globally, working with our partners.

Learn more

[IMG: People walking seen from above]

[H3]
Ethics, Risk and Compliance
To meet the expectations society has of our industry, we strive to maintain high ethical standards, manage risk effectively and ensure we comply with applicable laws and regulations.

[IMG: Trees seen from below]

[H3]
Environmental Sustainability
We understand the link between the health of our planet and the health of our patients. We are making progress in reducing the environmental impact of our operations in line with our near- and long-term targets.

[IMG: Portrait of Elon Mathieson]

[H3]
Inclusion
We foster an inclusive culture, believing it fuels innovation, drives engagement, and attracts talent.

We aim to conduct business responsibly wherever we operate with a focus on building a strong ethical foundation, respect for human rights, patient health and safety, inclusion and the safety and well-being of our employees. We have clear commitments on many other social topics including the living wage, product quality and use of animals in research.

[H2] Corporate governance
Our corporate governance framework supports sustainable financial performance and long-term value creation and is aligned with our values and behaviors. In a rapidly changing business environment, we apply effective risk management to build resilience. We continue taking important steps to integrate our ESG agenda into the core of our business, enhancing executive accountability and measuring our performance against transparent targets. Members of the Executive Committee and other senior leaders have ESG targets in their annual objectives.
[H2] Transparent reporting
Transparent reporting has been a central part of our commitment for many years and we continue to make progress in this area.

[IMG: People relaxing in the Novartis Basel campus]

[H2]
Environmental, Social and Governance (ESG) Index

Our ESG index provides an overview of various topics of interest to investors, analysts, and other stakeholders. We aim to report comprehensively and transparently on our actions, objectives and progress. The ESG index also shows where disclosures can be found across our publications and website.

Learn more

[IMG: Business people walking on the Novartis Basel campus]

[H3]
Reporting and transparency hub
Read our regulatory filings; policies, codes and guidelines that govern our activities; and environmental, social and governance (ESG) disclosures.

[IMG: Business people in a meeting]

[H3]
Positions on key topics
As part of our ongoing commitment to transparency, we state our position on key issues affecting our business and of specific interest to our stakeholders.

[IMG: Three business people discussing on Novartis campus]

[H3]
Awards & recognition
Novartis is honored to receive numerous awards for progress in research and development, our working environment, and our ESG activities.

[IMG: People walking on Novartis Campus]

[H3]
ESG rating performance
Our performance against environmental, social and governance criteria is reflected in a variety of third-party ratings.

[IMG: K Malesh, a farmer in the village of Sollakpally, now has ready access to water to irrigate his crops.]

[H2]
Water project revives rural community in India

Novartis is aiming for water neutrality in our own operations by 2030. In India, we are contributing to this goal through a project near Hyderabad with a nonprofit organization. By tackling both water scarcity and the deprivation it causes, the project has revived the community.

Read more

[IMG: Sister Martine, a trained nurse, dispensing medicine at the Catholic mission’s health center in Ntui, Cameroon.]

[H2]
A partnership against epilepsy

Parts of Cameroon have rates of epilepsy that are among the highest in the world. Despite the availability of effective therapies, poverty, a lack of medical resources and superstition about the causes of epilepsy often lead to inadequate treatment and social exclusion for people living with the neurological condition. Novartis is working with a Catholic mission on the ground in a central part of the country to overcome these barriers and improve care.

Read more

[H3]

Novartis Refugee Program

Novartis has redesigned and scaled our response to the global refugee crisis: going beyond monetary and medicine donations to offer an innovative, inclusive and differentiated approach that is holistic and sustainable.

Learn more

Novartis is a global company and its policies and programs, including those described in the Novartis in Society Integrated Report, may differ depending on the jurisdiction in which it operates. Novartis is committed to complying with the law in the countries and jurisdictions in which it conducts business.

[H1] Products
Below is a list of the treatments we currently offer via our US and International units. Please note: Not all treatments are available in all countries.

[H3] Adakveo®
(crizanlizumab)

Oncology

Available in
USA Product Site

United States

[H3] Afinitor Disperz®/Votubia®
(everolimus)

Oncology

Available in
https://www.afinitor.com/

USA Product Site

United States

Germany

Australia

United Kingdom

Austria

Poland

Netherlands

Canada

Turkey

Russia

[H3] Afinitor®/Votubia®
(everolimus)

Oncology

Available in
https://www.afinitor.com/

USA Product Site

United States

Germany

Australia

United Kingdom

Austria

Poland

Netherlands

Canada

Turkey

Russia

[H3] Aimovig®
(erenumab)

Neuroscience

Available in
https://www.aimovig.com/

USA Product Site

United States

Russia

[H3] Alomide

Available in
United States

[H3] Arzerra®
(ofatumumab)

Oncology

Available in
United States

Finland

Germany

Australia

United Kingdom

Austria

Poland

Netherlands

Canada

Turkey

Japan

[H3] Azarga®/Azorga®
(brinzolamide, timolol)

Ophthalmology

Available in
Germany

Australia

Austria

Poland

Netherlands

Canada

Japan

[H3] Beovu®
(brolucizumab)

Ophthalmology

Available in
United States

Russia

[H3] Betoptic S®

Available in
United States

[H3] Ciprodex®
(ciprofloxacin, dexamethasone)

Ophthalmology

Available in
Canada

[H1] Novartis Pipeline
Benefiting from our continued focus on innovation, Novartis has one of the industry’s most competitive pipelines. Many of these projects, which include new molecular entities as well as additional indications and different formulations for marketed products, are for medicines that could significantly advance treatment standards for patients worldwide. This table provides an overview of selected projects in development. Please note: the Novartis Pipeline data is updated quarterly.Download the Compounds in development (PDF 0.1 MB) section of the 2025 Annual Report

AAA601
Lutathera®
Gastroenteropancreatic neuroendocrine tumors

Oncology: Solid Tumors
Phase 3
2028
Radioligand therapy target SSTR

Supplementary Indication

AAA601
Lutathera®
GEPNET, pediatrics

Oncology: Solid Tumors
Phase 2
Radioligand therapy target SSTR

AAA603
177Lu-NeoB
Breast cancer

Oncology: Solid Tumors
Phase 1
Radioligand therapy target GRPR

AAA603
177Lu-NeoB
Multiple solid tumors

Oncology: Solid Tumors
Phase 2
≥ 2029
Radioligand therapy target GRPR

Lead Indication

AAA614
AAA614
Solid tumors

Oncology: Solid Tumors
Phase 2
Radioligand therapy target FAP

Lead Indication

AAA617
Pluvicto®
Oligometastatic prostate cancer

Oncology: Solid Tumors
Phase 3
≥ 2029
Radioligand therapy target PSMA

Supplementary Indication

AAA617
Pluvicto®
Metastatic hormone sensitive prostate cancer (mHSPC)

Oncology: Solid Tumors
Registration
Radioligand therapy target PSMA

Supplementary Indication

AAA817
225Ac-PSMA-617
Metastatic castration-resistant prostate cancer (mCRPC)

Oncology: Solid Tumors
Phase 3
≥ 2029
Radioligand therapy target PSMA

Supplementary Indication

AAA817
225Ac-PSMA-617
post Lu Metastatic castration-resistant prostate cancer (mCRPC)

Oncology: Solid Tumors
Phase 3
2028
Radioligand therapy target PSMA

Lead Indication

ABL001
Scemblix®
Chronic myeloid leukemia, pediatrics

Oncology: Hematology
Phase 2
2027
BCR-ABL inhibitor

Supplementary Indication

AIN457
Cosentyx®
Polymyalgia rheumatica

Immunology
Registration
2026
IL17A inhibitor

Supplementary Indication

AMG334
Aimovig®
Migraine, pediatrics

In-market Brands and Global Health
Phase 3
2028
CGRPR antagonist

Supplementary Indication

AMO959
AMO959
Prostate cancer

Oncology: Solid Tumors
Phase 1
DNA PK inhibitor

Lead Indication

BAF312
Mayzent®
Multiple sclerosis, pediatrics

Neuroscience
Phase 3
2027
S1P1,5 receptor modulator

Supplementary Indication

BYL719
Vijoyce®
Lymphatic malformations

Oncology: Solid Tumors
Phase 3
≥ 2029
PI3K-alpha inhibitor

Supplementary Indication

CYX082
farabursen
Autosomal dominant polycystic kidney disease

Cardiovascular, Renal and Metabolic
Phase 1
MIR17 inhibitor

Lead Indication

DAK539
pelabresib
Myelofibrosis

Oncology: Hematology
Phase 3
2026
BET inhibitor

Lead Indication

DFT383
DFT383
Cystinosis

Neuroscience
Phase 1
CTNS gene delivery

Lead Indication

DII235
DII235
CVRR-Lp(a)

Cardiovascular, Renal and Metabolic
Phase 2
≥ 2029
siRNA targeting Lp(a) MRNA

Lead Indication

DWH213
del-brax
Facioscapulohumeral muscular dystrophy

Neuroscience
Phase 3
2028
siRNA DUX4 knockdown

Lead Indication

Disclaimer
This information was factually accurate on the date it was published. Novartis assumes no duty to update the information to reflect subsequent developments. Readers should not rely upon the information on this page as current or accurate after its publication date. For the latest information on the Novartis' pipeline, readers should visit the News and Investors sections of our website. This information constitutes forward-looking statements relating to Novartis AG's business, including express or implied discussions regarding potential new products, potential new indications for existing products, or regarding potential future revenues from any such products. Such forward-looking statements reflect the current views of Novartis AG regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that any new products will be approved for sale in any market, or that any new indications will be approved for existing products in any market, or that such products will achieve any particular revenue levels.
In particular, management's expectations could be affected by, among other things, uncertainties involved in the development of new pharmaceutical products; unexpected clinical trial results, including additional analysis of existing clinical data or unexpected new clinical data; unexpected regulatory actions or delays or government regulation generally; the Novartis Group's ability to obtain or maintain patent or other proprietary intellectual property protection, including the uncertainties involved in the US litigation process; competition in general; government, industry, and general public pricing and other political pressures; and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected.

We are an innovative medicines company with research and development at our core. Our R&D engine powers an industry-leading pipeline focused on delivering transformative medicines to fight disease, restore possibility and help people live life on their own terms.

Researchers in Biomedical Research work across several diseases areas to uncover insights into the origins and pathogenesis of disease to drive drug discovery and early development, while the Development organization leads the advanced clinical development of those medicines, running large clinical trials and steering the way to regulatory approval and access for patients.This work is powered by technology platforms that help us innovate across our core therapeutic areas: Cardiovascular, Renal and Metabolic, Oncology, Immunology, and Neuroscience. We focus on two established platforms – chemistry and biotherapeutics – as well as three advanced platforms – xRNA, radioligand therapy, and gene and cell therapy – we believe will continue to play an increasingly important role in delivering new medicines for patients.

[IMG: Fiona H. Marshall, Ph.D]

[H3] "By building on our strengths, including our long history of scientific innovation and technological leadership, we aim to discover the next generation of medicines that will make a real difference to people’s lives"
Fiona H. Marshall, President, Biomedical Research

Read biography

[IMG: Shreeram Aradhye, President, Development and Chief Medical Officer]

[H3] "Our greatest impact comes from collaborating with those who share our purpose to develop new medicines that enable physicians to change their practice and ultimately reach all people who can benefit from them."
Shreeram Aradhye, President, Development and Chief Medical Officer

Read biography

[IMG: Biologists at Novartis collaborating to develop new medicines]

[H3]
Our research areas
We discover and advance innovative treatments for diseases with high unmet need

[IMG: Novartis researchers are working on an experimental, regenerative medicine in osteoarthritis.]

[H3]
Our pipeline
We maintain a focused portfolio of investigational medicines intended to alleviate society’s greatest disease burdens

[IMG: Tyler Patron researches cystic fibrosis]

[H3]
Our technology platforms
We’re pursuing platforms that offer more targeted approaches to treat patients

[IMG: Doctor explaining a scan to their patient]

[H2]
Clinical trials

Clinical trials are at the heart of our work to bring innovative medicines to people with a particular disease or condition. These studies ensure that an investigative medicine is effective and safe, and rely entirely on patients and healthy volunteers. Learn more about clinical trials at Novartis including opportunities to get involved.

Learn More

[IMG: Two scientists examine a slide]

[H2]
Postdoc program

This program grants appointments to postdocs at Novartis for up to four years under dual mentorship from a Novartis mentor and an academic mentor.

Learn More

[IMG: two scientists collaborating]

[H2]
Collaborations

Our science is deeply interconnected and nimble, open and accepting of criticism, prioritized to win in a competitive landscape, and – most importantly –  impatient in its delivery to patients.Our research benefits from an external network of more than 300 academic and 100 industry alliances focused on areas of mutual scientific interest.

Learn more

[IMG: Two scientists in a lab testing samples.]

[H3]
A legacy of blood cancer innovation
Building on more than two decades of chronic myeloid leukemia research, the R&D teams at Novartis pursued an investigational treatment unlike any other.

[IMG: A highly trained Novartis specialist dresses in full personal protective equipment to work on the radioligand therapy production line]

[H3]
Drug delivery, service delivery, and the future of cancer care
State-of-the-art Novartis manufacturing facility in Indianapolis fortifies the foundation of an entirely new paradigm in pharmaceutical drug delivery.

[IMG: portrait of Dr Bülent Kızıltan, Global Head of AI & Computational Sciences]

[H3]
From black holes to AI driven drug discovery – collaboration wins the day
Dr Bülent Kızıltan, Global Head of AI & Computational Sciences

More stories

[H3]
Recent jobs in research

Novartis looks for dedicated team members to join its research efforts around the world. We recruit the best and brightest at all levels of expertise.

Novartis looks for dedicated team members to join its research efforts around the world. We recruit the best and brightest at all levels of expertise.

Sales, China, International

(高级）医药代表 /（资深）产品专员

Marketing, China, International

(Senior) Brand Manager- IMMU

Audit & Finance, Mexico, Finance

FRA Accountant

Sales, China, International

(高级）医药代表 /（资深）产品专员

[H3]

Translational medicine research at Novartis

Too often, new therapies fail to bridge the treacherous gap that lies between research and entry into human clinical testing. Our team of translational medicine researchers work to bridge this gap and ensure that safe, effective and innovative treatments reach patients as quickly as possible.

Read more

Patients and caregivers know better than anyone what it is like to live with a serious disease. We listen. And we learn from people’s experiences. We work together to create medicines that address the needs of people living with disease and achieve the results that matter to them.

[H2]
The Novartis commitment to patients and caregivers

We recognize the importance of patients and caregivers understanding what they can expect from Novartis.

Learn more

[H2] Our work with patients and caregivers is built on four commitments

[H3] 1. Respecting and understanding the patient community perspective
[H3] 2. Expanding access to our medicines
[H3] 3. Conducting responsible clinical trials
[H3] 4. Recognizing the importance of transparency and reporting
Read more about our commitment to patients and caregivers here.

40+

Patient organizations represented

Download the 2025 factsheet (PDF 1.2 MB)

77k+

Novartis associates own it as an aspiration*

[IMG: doctor and nurse]

[H2]
Disclosure of patient organization funding

Novartis annually discloses monetary and non-monetary support to patient organizations around the globe by June 30.

Learn more

[H2] Our commitment – reporting 2025 progress

[H3] 94%
[H4] early research programs
in general medicines were developed with patient perspective and insights before first-in-human trials (healthy volunteers).
[H3] 7 194
[H4] new patients were reached through managed access programs
with 94% of requests approved for 37 compounds in 62 countries. MAPs provide access to locally unauthorized Novartis medicines.
[H3] 81
[H4] clinical development projects
consulted people living with a disease on the design and/or conduct of clinical trials.
[H3] 191
[H4] Clinical trials
with patient reported outcomes (PRO) were conducted in 81 countries.
[H3] 402
[H4] Simplified summaries
from Phase I-IV clinical trials were sent to investigators to share with over 71 000 trial participants and posted on novartis.com/clinicaltrials.
[H3] 30 m
[H4] Patients
reached through access approaches.

[H2]
Clinical Trials

[IMG: healthcare professionals clinical trials in progressclinical trials]

[H3]
About clinical trials
Clinical trials are scientific studies conducted to find better ways to prevent, screen for, diagnose or treat disease.

[IMG: A doctor speaks with a patient]

[H3]
Participating in Novartis clinical trials
Novartis is currently conducting clinical trials around the world for a number of diseases.

[IMG: patients caregivers managed access]

[H3]
Managed access programs
Novartis managed access makes investigational or unapproved treatments available to eligible patients with serious or life-threatening diseases. Your physician may request access.

[IMG: Portrait of a patient and a healthcare professional]

[H3]
Diversity
Diversity in clinical trials helps us improve the quality of care for every patient, while also helping to address health inequities in society. We are working to improve both the diversity of patients enrolled in our clinical research and the investigators involved in our trials.

[H3] Collaborations with patient organizations

[IMG: Japanese doctor and patients discussing illness]

[H2]
Listening to the CML patient community

Improving the patient experience and removing potential barriers to clinical trial participation

Read more

[IMG: Doctor with senior woman in an office]

[H2]
Patient organizations and Novartis

Working together with patient organizations and healthcare organizations helps us create better medicines. This collaboration is based on values of mutual respect, trust and transparency.

Learn more

[IMG: men handshake_0]

[H2]
External funding

Novartis may provide funding to legitimate organizations to support its mission to discover new ways to improve and extend people's lives, advance scientific and medical knowledge, and supporting the communities where Novartis associates live and work.

Learn more

[IMG: mother daughter hug]

[H2]
Patient perspectives

Patients and caregivers know better than anyone what it is like to live with a serious disease. Visit our YouTube channel to watch our patient stories to learn more about insights from the patient community.

Watch the videos

For questions about Novartis, medical inquiries about our products and/or information about services, we recommend you contact the Novartis office in your country. If you’re seeking a global list of products, visit our Global Product Portfolio.

Country contacts
Novartis directory
Global product portfolio
Report side effects

*Based on 2025 data.